Loading...
Loading...
APGN| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 8,799.0K |
| Operating I/L | -8,799.0K |
| Other Income/Expense | 307.0K |
| Interest Income | 0.0K |
| Pretax | -8,492.0K |
| Income Tax Expense | -307.0K |
| Net Income/Loss | -8,185.0K |
Apexigen Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody therapeutics for oncology. The company's pipeline includes APX005M, a humanized agonist antibody in Phase II clinical development for the treatment of solid tumors, and APX601, a humanized antagonist antibody in Phase I/II clinical trial for multiple tumor indications. Additionally, the company is developing APX801, an NK cell engager designed to activate natural killer cells for the killing of tumor cells. Apexigen generates revenue through the development and potential commercialization of these antibody therapeutics for the treatment of various cancers.
